psma prostate cancer lapaʻau

ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA He holomua koʻikoʻi i ka mālama ʻana i ka maʻi maʻi prostate, ʻoi aku ka metastatic castration-resistant prostate cancer (mCRPC). Ke ʻimi nei kēia alakaʻi i nā ʻokoʻa ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA nā koho, me ka radioligand therapy, ko lākou pono, nā hopena ʻaoʻao, a pehea lākou e hoʻololi ai i ka ʻāina o ka mālama ʻana i ka maʻi maʻi prostate. E aʻo e pili ana i ka ʻepekema ma hope o PSMA, nā lāʻau lapaʻau like ʻole i loaʻa, a me nā mea e hiki i nā mea maʻi ke manaʻo i ka wā o ka mālama ʻana. ʻO ka hoʻomaopopo ʻana i ka PSMA a me kāna kuleana i ka maʻi maʻi prostate ʻo Prostate-Specific Membrane Antigen (PSMA) he protein i hōʻike nui ʻia ma luna o ka ʻili o nā maʻi maʻi prostate, ʻoi aku ka nui o nā maʻi holomua a me ka metastatic. He aha ka PSMA? ʻOiai ke noiʻi ʻia nei kāna kuleana physiological pololei, ua ʻike ʻia ʻoi aku ka kiʻekiʻe o ka ʻōlelo PSMA i nā maʻi maʻi prostate i hoʻohālikelike ʻia i ka ʻiʻo prostate maʻamau a me nā mea ʻē aʻe o ke kino. ʻO kēia hōʻike ʻoi aku ka mea i ʻike nui ʻia no ka maʻi maʻi prostate imaging a me ka therapy.No ke aha ʻo PSMA kahi pahuhopu maikaʻi no ka mālama ʻana i ka maʻi maʻi prostate? He mea koʻikoʻi kēia koho no ka hōʻemi ʻana i nā hopena ʻaoʻao a hoʻomaikaʻi i ka index therapeutic o ka mālama ʻana i ka maʻi maʻi prostate. Eia kekahi, piʻi aʻe ka ʻōlelo PSMA i ka holomua ʻana o ka maʻi maʻi prostate, e hoʻolilo iā ia i pahuhopu waiwai ʻoiai i nā pae kiʻekiʻe o ka maʻi. ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA Ua hoʻomohala ʻia nā ʻano hana, e hoʻohana ana i nā hiʻohiʻona kūʻokoʻa o PSMA e hoʻopuka pololei i nā mea lapaʻau i nā pūnaewele maʻi prostate. Hoʻokomo ʻia kēia radiopharmaceutical i loko o ka mea maʻi, kahi e kaapuni ai i ke kahe koko a paʻa paʻa i ka PSMA-expressing prostate cancer cells. Hoʻopuka ka isotope radioactive i ka pāhawewe e hōʻino a pepehi paha i nā pūnaeho maʻi maʻi. ʻO kahi laʻana koʻikoʻi ʻo Lutetium-177 (177Lu) PSMA-617.Pehea e hana ai: Hoʻopaʻa ʻia kahi molekele huli (e laʻa, PSMA-617) iā PSMA ma nā pūnaewele maʻi prostate. ʻO kahi isotope radioactive (e laʻa, Lutetium-177) e hāʻawi i ka radiation i nā pūnaeho maʻi maʻi. Hoʻopilikia ka radiation i ka DNA o nā maʻi kanesa, e alakaʻi ana i ka make cell.Pono: Ua hōʻike nā hoʻokolohua lapaʻau i ka maikaʻi o ka RLT i hoʻopaʻa ʻia e PSMA i ka hoʻomaikaʻi ʻana i ke ola holoʻokoʻa a me ka maikaʻi o ke ola i nā maʻi me ka mCRPC. ʻO ka hoʻāʻo ʻo VISION, no ka laʻana, hōʻike i kahi pōmaikaʻi ola nui me 177Lu-PSMA-617 me ka maʻamau o ka mālama ʻana i hoʻohālikelike ʻia me ke kūlana mālama wale nō. Kipa Shandong Baofa Cancer Research Institute e aʻo hou e pili ana i nā holomua o ka maʻi maʻi maʻi.Nā hopena ʻaoʻao: ʻO nā hopena ʻaoʻao maʻamau o ka RLT i hoʻopaʻa ʻia e PSMA, ʻo ia ka luhi, ka waha maloʻo, ka nausea, ka hoʻopau ʻana i ka momona o ka iwi (e alakaʻi ana i nā helu koko haʻahaʻa), a me nā pilikia kīkī. Hiki ke mālama ʻia kēia mau hopena ʻaoʻao me ke kākoʻo. Ke hoʻopaʻa ʻia ka antibody i ka PSMA ma ka cell cancer, hoʻokomo ʻia ka ADC, a hoʻokuʻu ʻia ka lāʻau chemotherapy i loko o ke keʻena, a make ia.Pehea e hana ai: Hoʻopili ʻia kahi antibody i ka PSMA ma nā pūnaewele maʻi prostate. Hoʻokomo ʻia ka ADC i loko o ke kelepona. Hoʻokuʻu ʻia ka lāʻau chemotherapy i loko o ke keʻena, e alakaʻi ana i ka make cell.Pono: Ke kūkulu ʻia nei nā ADC i manaʻo ʻia e PSMA, akā ua hōʻike ʻia nā hoʻokolohua lapaʻau mua i nā hopena hoʻohiki i nā maʻi me ka mCRPC. Hiki ke ʻokoʻa ka hopena ma muli o ka ADC kikoʻī a me nā ʻano maʻi.Nā hopena ʻaoʻao: Hoʻopili ʻia nā hopena ʻaoʻao i ka lāʻau chemotherapy i hoʻohana ʻia i ka ADC a hiki ke komo i ka nausea, ka luhi, ka poho o ka lauoho, a me ka hoʻopau ʻana i ka iwi iwi. ʻAe kēia i nā kauka e ʻike i ka wahi a me ka nui o ka maʻi, loiloi i ka pane ʻana i ka lāʻau lapaʻau, a koho i nā maʻi i loaʻa ka pōmaikaʻi mai nā lāʻau lapaʻau i hoʻopaʻa ʻia e PSMA. Hoʻohālikelike kēia ala i ka theranostics, hoʻohui i nā diagnostics a me nā therapeutics.Pehea e hana ai: Hoʻokomo ʻia kahi mea hoʻokele radioactive (e laʻa, Gallium-68 PSMA-11 a i ʻole Fluorine-18 DCFPyL) i loko o ka mea maʻi. Hoʻopili ka tracer i ka PSMA ma nā pūnaewele maʻi prostate. Hana ʻia kahi scan PET/CT e ʻike i ka wahi a me ka nui o ka maʻi.Pono: ʻO ke kiʻi kiʻi i hoʻopaʻa ʻia ma PSMA he mea koʻikoʻi a kikoʻī no ka ʻike ʻana i ka maʻi prostate, me ka metastases. Hiki iā ia ke ʻike i ka maʻi i ʻike ʻole ʻia ma nā ʻano hana kiʻi maʻamau. Hiki i kēia ʻike ke alakaʻi i nā hoʻoholo lapaʻau a hoʻomaikaʻi i nā hopena maʻi.Nā hopena ʻaoʻao: Palekana maʻamau ke kiʻi kiʻi ʻia e PSMA, me nā hopena ʻaoʻao liʻiliʻi. ʻO nā mea radioactive tracers i hoʻohana ʻia he pōkole hapalua-ola a hoʻopau koke ʻia mai ke kino. ʻO wai ka Moho no ka PSMA-Targeted Therapy?ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA noʻonoʻo ʻia no nā poʻe maʻi me ka metastatic castration-resistant prostate cancer (mCRPC) i holomua ma nā lāʻau maʻamau e like me ka androgen deprivation therapy a me ka chemotherapy. Loaʻa i nā moho kūpono ka hōʻike PSMA kiʻekiʻe i ko lākou mau maʻi koko, e like me ka hoʻoholo ʻana e ka PSMA-PET kiʻi. ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA he mea koʻikoʻi no ka hoʻonui ʻana i ka pono a me ka hōʻemi ʻana i ka hopena o nā hopena ʻaoʻao. ʻO nā koʻikoʻi koʻikoʻi he: Metastatic castration-resistant prostate cancer (mCRPC) Holomua i nā lāʻau maʻamau (e laʻa, androgen deprivation therapy, chemotherapy) Hōʻike PSMA kiʻekiʻe i loko o nā ʻōpū, e like me ka hoʻoholo ʻana e PSMA-PET imaging ʻO ka hana o ka PSMA-PET Kiʻi i ka hoʻolālā lapaʻau ʻo PSMA-PET kiʻi i ka hoʻolālā ʻana i ka poʻe maʻi i hoʻopaʻa ʻia e ʻike i ka nui o ka poʻe maʻi i hoʻolālā ʻia e PSMA-PET i ka hoʻolālā lapaʻau e hoʻokani ana i ka pono o ka poʻe maʻi. nā lāʻau lapaʻau. ʻO nā maʻi me ka hōʻike PSMA kiʻekiʻe i ko lākou mau maʻi koko e ʻoi aku ka maikaʻi o ka pane ʻana i ka lāʻau lapaʻau, ʻoiai ʻaʻole pono ka poʻe me ka ʻōlelo PSMA haʻahaʻa. ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA hiki ke ʻokoʻa ma muli o ka lāʻau lapaʻau i hoʻohana ʻia. Eia naʻe, aia kekahi mau mea maʻamau e makaʻala. Hiki i nā maʻi ke loaʻa i nā pōʻai he nui o ka mālama ʻana, e hoʻokaʻawale ʻia i kekahi mau pule. I ka wā o ka mālama ʻana, nānā pono ʻia nā mea maʻi no nā hopena ʻaoʻao a me ka pane ʻana i ka lāʻau. Hiki ke mālama ʻia kēia mau hopena ʻaoʻao me ka mālama kākoʻo, e like me nā lāʻau lapaʻau e hōʻoluʻolu ai i ka nausea a me ka ʻeha, nā kahe koko e mālama ai i ka anemia, a me ka hydration e kākoʻo i ka hana kīkī. He mea nui ka nānā mau ʻana i ka helu koko a me ka hana ʻana i ka hana ʻana i ka wā mālama. ʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA ke ulu wikiwiki nei, me ka noiʻi mau ʻana e ʻimi ana i nā lāʻau lapaʻau hou a i hoʻomaikaʻi ʻia. Ke noiʻi mau nei ka ʻimi noiʻi a me nā hoʻāʻo hoʻāʻo ʻana nā mea noiʻi e noiʻi ana i nā radioligands hou i hoʻopaʻa ʻia ma PSMA me ka hoʻomaikaʻi ʻana i ka pono a me ka palekana. ʻO nā lāʻau lapaʻau hoʻohui, e like me ka hoʻohui ʻana i ka PSMA-targeted RLT me nā lāʻau lapaʻau ʻē aʻe e like me immunotherapy a i ʻole chemotherapy, ke ʻimi ʻia nei hoʻi. Shandong Baofa Cancer Research Institute Ua kūpaʻa ʻo ia e noho ma ka poʻo o kēia mau holomua.Nā holomua i ka PSMA-Targeted Therapies ʻO nā holomua i ka wā e hiki mai ana i nā lāʻau lapaʻau i hoʻopaʻa ʻia ma PSMA e komo paha: More potent radioactive isotopes Improved targeting molecules with higher affinity for PSMA Combination therapies that enhance the efficacy of PSMA-targeted RLT Lapaʻau ʻana i ka maʻi maʻi maʻi Prostate Hōʻuluʻulu manaʻoʻO ka mālama ʻana i ka maʻi maʻi prostate PSMA He ala maikaʻi loa ia no ka mālama ʻana i ka maʻi maʻi prostate. Ma ke koho ʻana i ka PSMA e hōʻike ana i nā maʻi kanesa prostate, hiki i kēia mau lapaʻau ke hoʻomaikaʻi i nā hopena a me ka maikaʻi o ke ola no nā poʻe maʻi me ka mCRPC. Ke hoʻomau nei ka noiʻi, hiki iā mākou ke manaʻo e ʻike i nā holomua hou aʻe i kēia kahua, e alakaʻi ana i nā lāʻau lapaʻau ʻoi aku ka maikaʻi a pilikino no ka maʻi maʻi prostate. Hoʻohālikelike i nā ʻano hoʻomaʻamaʻa PSMA-Targeted Therapy Type Mechanism Key Example Status PSMA-Targeted Radioligand Therapy (RLT) Hāʻawi pololei i ka radiation i nā cell e hōʻike ana i ka PSMA Lutetium-177 (177Lu) PSMA-617 Apono ʻia no ka mCRPC PSMA-Targeted Antibody-Drug Conjugates (ADC-Drug Conjugates) - ma lalo o ka hoʻomohala ʻia ʻana) Nā hoʻāʻo hoʻokolohua PSMA-Targeted Kiʻi ʻike ʻike i ka hōʻike PSMA no ka maʻi a me ka hoʻolālā lāʻau Gallium-68 PSMA-11, Fluorine-18 DCFPyL ʻApono ʻia no ke kiʻi. Hōʻole: No ka hoʻonaʻauao wale nō kēia ʻike a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E ʻoluʻolu e kamaʻilio me kahi ʻoihana mālama olakino kūpono no ka maʻi a me nā koho lapaʻau.